Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patient...
6 transactions — including 0 buys declared by Xeris Biopharma Holdings, Inc. executives to SEC / AMF / BaFin.
16 institutional funds report a position on XERS in their latest SEC quarterly filing.
15 recent articles on XERS.
Beyond raw data, we aggregate and score every smart money signal to give you a unique view.
8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.
Automatic detection when 3+ executives buy the same stock simultaneously — historically the most reliable signal.
Berkshire (Buffett), Pershing Square (Ackman), Tiger Global, Bridgewater + 200 more. Who buys what, each quarter.
NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.
Spot small caps whose retail interest explodes before the rest of the market. 100+ tickers monitored.
Create your watchlist and receive every morning at 8am the Brief of events on YOUR tickers.
This public page only shows a preview. The full analysis of XERS on the Kairos Insider dashboard includes:
Free signup · Premium €29/month no commitment